CRISPR: editing the drug discovery workflow
(WorldNews Switzerland)

By Enrique Neumann Gene editing is crucial to pharmaceutical development. CRISPR-Cas9 promises to revolutionize the role gene editing plays in drug discovery and even therapeutics. CRISPR-CAS9 gene editing complex from Streptococcus pyogenes. The hype CRISPR was hailed by Science magazine as their 2015 Breakthrough of the Year. The phenomenal hype around this method can be measured by the number of deals being made by leading companies such as AstraZeneca, Novartis, and Juno Therapeutics with various gene-editing companies. One deal alone is valued at $2.6 billion. AstraZeneca, for example, sees the technology as a powerful solution to the R&D challenges that plague the pharmaceutical...